High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study.
In order to evaluate the effect of intensive combined chemotherapy in pediatric brain tumors, we designed a phase II study of high-dose busulfan and thiotepa followed by bone marrow transplantation (BMT) in children with measurable recurrent brain tumors. As alkylating agents, busulfan and thiotepa were expected to exhibit a steep dose effect and no overlapping extramedullary toxicity. Moreover, both drugs have an excellent distribution into the central nervous system in humans. Since May 1988, 20 children (median age 6 years) have been treated. Busulfan (150 mg/m2/day x 4) given orally was followed by thiotepa (350 mg/m2/day x 3), given as a 1 h i.v. infusion. Cryopreserved bone marrow was reinfused 48 h after completion of chemotherapy. Tumor response was assessed by computed tomography and magnetic resonance imaging 4 to 6 weeks after BMT. Five partial responses were observed (three of six medulloblastomas, one of five ependymomas, one of two primitive neuroectodermal tumors); two patients with medulloblastoma and one with brain stem tumor achieved an objective response. Ten patients had stable disease and one progressive disease. One patient is not evaluable because of early toxic death. Toxicity was high in terms of aplasia and cutaneous, hepatic and neurological complications. The overall response rate of 26% is encouraging since all patients had disease refractory to all conventional therapies.
Kalifa
C
C
Pediatric Department, Institut Gustave-Roussy, Villejuif, France.
Hartmann
O
O
Demeocq
F
F
Vassal
G
G
Couanet
D
D
Terrier-Lacombe
M J
MJ
Valteau
D
D
Brugieres
L
L
Lemerle
J
J
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects; D016026:Bone Marrow Transplantation; D001932:Brain Neoplasms / Q000188:drug therapy / Q000601:surgery*; D002066:Busulfan / Q000008:administration & dosage* / Q000009:adverse effects; D002490:Central Nervous System / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004064:Digestive System / Q000187:drug effects; D003875:Drug Eruptions / Q000209:etiology; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007223:Infant; D008099:Liver / Q000187:drug effects; D008297:Male; D013852:Thiotepa / Q000008:administration & dosage* / Q000009:adverse effects
D013852:Thiotepa; D002066:Busulfan